Literature DB >> 1467200

Methodology and assessment in clinical anti-emetic research: a meta-analysis of outcome parameters.

G R Morrow1.   

Abstract

There have been major clinical advances in the control of chemotherapy-induced nausea and emesis. These advances were achieved partly by the introduction of new anti-emetic agents but important improvement came from the use of existing agents in ways developed from the results of studies based on new approaches and methods in anti-emetic research. By developing basic research tools, improving methodology and applying psychometrically sound assessments better management or chemotherapy-induced nausea and vomiting has been achieved. The goals of anti-emetic assessment are discussed here along with data and examples of assessment techniques for emesis and nausea. Examination of 153 separate anti-emetic studies between the years of 1975 and 1988 showed that emesis was the most common outcome measure used and that approximately 1 out of five studies measured some other type of outcome usually in the context of nausea and emesis. The frequency of outcome events was most commonly the dimension assessed. Examination of size of the effect of an anti-emetic regimen for these anti-emetic studies showed it to be independent of the type of outcome measured, but to be quite dependent on how the outcome was quantified. For instance, differences in the frequency or incidence of either nausea or emesis were generally larger than measurements made of the duration of either of these.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467200      PMCID: PMC2149627     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  15 in total

1.  Emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis.

Authors:  M Martin; E Diaz-Rubio
Journal:  Ann Oncol       Date:  1990       Impact factor: 32.976

Review 2.  Advances in data assessment. Application to the etiology of nausea reported during chemotherapy, concerns about significance testing, and opportunities in clinical trials.

Authors:  G R Morrow; P M Black; D J Dudgeon
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

Review 3.  Methodology of antiemetic trials: a review.

Authors:  M Tonato; F Roila; A Del Favero
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

4.  Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.

Authors:  M G Kris; R J Gralla; R A Clark; L B Tyson; S Groshen
Journal:  Cancer       Date:  1987-12-01       Impact factor: 6.860

5.  Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research.

Authors:  G R Morrow
Journal:  Cancer       Date:  1984-05-15       Impact factor: 6.860

6.  Assessment of nausea.

Authors:  A Del Favero; F Roila; C Basurto; V Minotti; E Ballatori; L Patoia; M Tonato; G Tognoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Advances in anti-emetic therapy.

Authors:  M T Bakowski
Journal:  Cancer Treat Rev       Date:  1984-09       Impact factor: 12.111

8.  GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.

Authors:  P J Hesketh; W K Murphy; E P Lester; D R Gandara; A Khojasteh; E Tapazoglou; G P Sartiano; D R White; K Werner; J M Chubb
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

9.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

10.  Methodology in anti-emetic trials.

Authors:  R J Gralla; R A Clark; M G Kris; L B Tyson
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  1 in total

Review 1.  Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.

Authors:  Snežana M Bošnjak; Richard J Gralla; Lee Schwartzberg
Journal:  Support Care Cancer       Date:  2017-01-20       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.